Baltimore diagnostics company Novel Microdevices was awarded up to $13.8 million from CARB-X, a global, nonprofit partnership based out of Boston University that supports R&D, to address the emergence of bacteria that is resistant to treatment drugs.
The funding will hep Novel Microdevices develop its molecular test for sexually transmitted infections, including chlamydia and gonorrhea. In the case of gonorrhea, treatment has become more difficult because the bacteria that causes the disease has developed resistance to antibiotics. Novel Microdevices’ test is being designed to test for those particular strains that are resistant to treatment, known as superbugs.
“Novel’s technology is in the early stages of development and, if successful, could be used world-wide to help health-care providers diagnose gonorrhea, including resistance markers, more rapidly, thus improving treatment decisions, and mitigating the devastating effects of these diseases,” said Erin Duffy, R&D chief of CARB-X, in a statement.
READ FULL ARTICLE HERE